Radiopharmaceutical medical imaging manufacturer Cyclopharm has revealed a possible new use for its Technegas system – for evaluating the progress of lung transplantation. The use is detailed in a US-based study which highlights the clinical utility and operational benefits of the Technegas technology compared to current US ventilation imaging radiopharmaceuticals used in lung transplant evaluation.…
ANSTO’s OPAL research reactor at Lucas Heights in Sydney has recommenced operations following a months-long planned shutdown to carry out essential maintenance and upgrades. Central to these upgrades was the elaborate replacement of OPAL’s cold neutron source, located next to the reactor core. The three-metre-tall device slows down neutrons as they travel from the OPAL…
Radiopharmaceutical developer entX Ltd is poised to make a decision to green light construction of a radiopharmaceutical production facility targeting cancer treatment with radioactive isotopes. The facility is supported by a $1.9 million Economic Recovery Fund (ERF) grant from the South Australian Government as well as a $2,915,000 Cooperative Research Centres Projects (CRC-P) grant announced…
Radiopharmaceutical system manufacturer Cyclopharm has entered into an agreement to supply the Veterans Health Administration (VA), the largest US government health care system, with the pharmaceutical and consumable components of its Technegas imaging system. The Interim Agreement immediately provides the 120 Veterans Affairs hospitals, which have nuclear medicine departments, access to an agreed contract for…
AnteoTech engages with EV manufacturers to incorporate its anode materials Clean energy technology company AnteoTech is now engaged at different levels with the majority of European EV manufacturers as they seek to incorporate higher performing anodes in their vehicle batteries. At the recent The Battery Show, in Stuttgart, Germany the company continued to move towards…
